Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery

Karissa E. Cottier, Emily A. Galloway, Elisa C. Calabrese, Margaret E. Tome, Erika Liktor-Busa, John Kim, Thomas P. Davis, Todd W. Vanderah, and Tally M. Largent-Milnes

DOI: http://dx.doi.org/10.1523/ENEURO.0116-18.2018

1Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724

Abstract

Cortical spreading depression (CSD) in the CNS is suggested as a common mechanism contributing to headache. Despite strong evidence for CNS involvement in headache disorders, drug development for headache disorders remains focused on peripheral targets. Difficulty in delivering drugs across the blood-brain barrier (BBB) may partially account for this disparity. It is known, however, that BBB permeability is increased during several CNS pathologies. In this study, we investigated BBB changes in response to KCl-induced CSD events and subsequent allodynia in rats. Cortical KCl injection in awake, freely moving rats produced facial allodynia with peak intensity between 1.5 and 3 h and CSD induction within 0.5–2 h postinjection. Brain perfusion of 14C-sucrose as a marker of BBB paracellular permeability revealed increased leak in the cortex, but not brainstem, beginning 0.5 h post-KCl injection and resolving within 6 h; no changes in tight junction (TJ) proteins occludin or claudin-5 expression were observed. Acute pretreatment with topiramate to inhibit CSD did not prevent the increased BBB paracellular permeability. CNS delivery of the abortive anti-migraine agent sumatriptan was increased in the cortex 1.5 h post-KCl injection. Surprisingly, sumatriptan uptake was also increased in the brainstem following CSD induction, suggesting regulation of active transport mechanisms at the BBB. Together, these results demonstrate the ability of CSD events to produce transient, time-dependent changes in BBB permeability when allodynia is present and to mediate access of clinically relevant therapeutics (i.e., sumatriptan) to the CNS.

Key words: blood-brain barrier; CNS; cortical spreading depression; drug delivery; headache; triptan

Significance Statement

The need to overcome the blood-brain barrier (BBB) is one of the major hurdles in designing CNS active drugs. CNS mechanisms have been shown to play a vital role in primary and secondary headache disorders. In this study, we show that BBB permeability is transiently increased in a rat model of cortical spreading depression (CSD)-induced episodic headache. We also observed a significant increase in sumatriptan uptake into the brain. Clinically, sumatriptan has been shown to be most efficacious when given close to the onset of headache pain, corresponding to times where we observed increased CNS uptake in our rat model. These data suggest that altered BBB permeability occurs during CSD and may be taken advantage of during therapeutic intervention.

Introduction

Headache is a common symptom of several neurologic disorders (Pitts et al., 2008; Tabatabai and Swadron, 2016). Disorders presenting with headache can be classified as either primary or secondary headache disorders depending on their underlying cause [Headache Classification Committee of the International Headache Society (IHS), 2013]. One mechanism implicated in both primary...
and secondary disorder production is cortical spreading depression (CSD; Olesen et al., 1990; Hajdikhani et al., 2001; Bolay et al., 2002; Dreier et al., 2006; Hartings et al., 2009; Zhang et al., 2010; Lauritzen et al., 2011; Woitzik et al., 2013; Chen and Ayata, 2016). CSD is described as a wave of self-propagating depolarization followed by hyperpolarization across the cortex (Leo 1944; Leo 1947; Somjen, 2001). Induced CSD events can lead to potentiation of excitotoxicity, production of CNS lesions, and changes in cerebral blood flow (Chen and Ayata, 2016). Additionally, CSD has been suggested to trigger activation and persistent sensitization of meningeal nociceptors, potentially contributing to the production of pain in headache disorders (Zhang et al., 2010; Zhao and Levy, 2016). CSD has been shown to elicit the release of pronociceptive and vasoactive substances including calcitonin gene-related protein (CGRP), glutamate, ATP, nitric oxide, potassium, and hydrogen ions in the cortex (Brennan et al., 2007; Russo, 2015). Some of these substances independently are reported to influence blood-brain barrier (BBB) permeability (Diler et al., 2007; Asghar, 2012; Eftekhar et al., 2015; Wang et al., 2015).

Previous studies have provided evidence that BBB permeability is altered following CSD. In addition to contributing to deleterious events in the CNS, altered BBB permeability has the potential to impact drug delivery to the CNS during and following CSD (Gursesoy-Ozdemir et al., 2004; Olah et al., 2013; Friedman and Kauffer, 2015). The BBB, at the level of the capillary endothelial cells, is the main CNS component involved in regulating the passage of substances from the circulating blood to the brain and vice versa (Abbott et al., 2010). The BBB is comprised of specialized endothelial cells joined together to form tight junctions (TJs) with high transendothelial cell resistance (TEER; Abbott et al., 2010). These TJs are comprised of TJ proteins, such as occludin and the claudins, which are anchored to the actin cytoskeleton by the zona occludens (ZO) linker proteins. Importantly, these interactions are dynamic, and therefore change in response to surrounding cues (Abbott et al., 2010). This dynamic nature of the BBB is regulated in part by the neurovascular unit (NVU). The NVU is comprised of numerous CNS cell types including endothelial cells, astrocytes, other glial cells, neurons, and pericytes (Hawkins and Davis, 2005). Based on the ability of the BBB to react to changes in CNS activity, it is highly likely that changes in BBB permeability occur in CNS disorders such as headache and pain.

Some preclinical work has suggested that BBB permeability is increased in response to CSD or headache pain (Gursesoy-Ozdemir et al., 2004). Separately, it has also been shown that KCl-induced CSD elicits nociceptive behaviors in rats; however, BBB permeability was not measured (Fioravanti et al., 2011). Additionally, examination of BBB permeability in a dural inflammation model of headache showed a site-specific increase in BBB permeability in the trigeminal nucleus caudalis (TNC), a brain region involved in transmission of nociceptive stimuli from the trigeminal afferents (Fried et al., 2017). A few clinical studies have also attempted to study BBB changes in response to primary headache disorders such as migraine but have produced conflicting results. While one study on spontaneous migraine with aura observed an increase in matrix metalloproteinase-9 (MMP-9), indicative of a BBB breach (Leira et al., 2007), another study in migraine with aura found increased perfusion at the brainstem only and no permeability changes at the cortex (Hougaard et al., 2017). No clinical or preclinical study to date, however, has successfully examined the temporal relationship between headache pain, CSD, paracellular BBB integrity and/or leak in the context of drug delivery.

In the current study, we hypothesized that CSD induced by a single KCl injection would increase paracellular CNS uptake of small molecules at discrete times during headache induction. Using a combinatorial approach of electrophysiology, behavioral measures, and in situ brain perfusion, we found that cortical KCl injection induced CSD and temporally increased paracellular BBB leakiness to radiolabeled sucrose in the cortex, but not in the brainstem. We also observed an increase in BBB permeability to sumatriptan in both the cortex as well as the brainstem, indicating the potential for changes in active transport activity.

Materials and Methods

Animals

Female Sprague Dawley rats (200–250 g) were purchased from Envigo and housed in a climate-controlled room on a regular 12/12 h light/dark cycle with lights on at 7 A.M. with food and water available ad libitum in the vivarium five floors below the lab. All procedures were performed during the light phase and according to the policies and recommendations of the International Association for the Study of Pain, the National Institutes of Health (NIH) guidelines for laboratory animals, and with approval from the Institutional Animal Care and Use Committee of the University of Arizona. For Number of Animals Consistent with NIH policy (NOT-OD-15-102) on relevant biological variables (e.g., strain, sex, and age) experiments were randomized to blinded treatment (topiramate, sumatriptan, or vehicle), injury (KCl or aCSF), and control groups, giving 80% power to detect a treatment effect size of 20% compared to a baseline response of 5% at a significance level of 0.05. Numbers required to achieve statistical power for each experiment were determined by G*Power 3.1. Female rats were used as headache disor-
Vaginal swarms

Estrous cycles of intact female rats were monitored by daily vaginal swarms. The vaginal swarms were interpreted as described by Goldman et al. (2007). Briefly, vaginal openings were flushed with 200 μl of sterile saline. Fresh samples were evaluated for cytology at the same time daily for at least 8 d using a Zeiss Axioskop 40 (10×/0.3 numerical aperture EC Plan-Neofluar objective, Carl Zeiss Microscopy). Cortical injections were given during the diestrous phase of the estrous cycle. CSD events, pain behaviors, and BBB permeability were also assessed during the diestrous phase; except in the case of multiple day assessments, where rats continued to progress through the estrous cycle.

Drugs and reagents

Ketamine/xylazine was purchased from Sigma-Aldrich. 14C-sucrose and optiphase supermix scintillation cocktail were purchased from PerkinElmer. 3H-sumatriptan was purchased from American Radiolabeled Chemicals Inc. Sumatriptan was generously donated by the Porreca Lab (University of Arizona; source: Abmole Bioscience). Topiramate was purchased from Cayman Chemical. TS-2 tissue solubilizer was purchased from Research Products International. EDTA-free complete protease inhibitors were purchased from Roche. The Coomassie Plus Better Bradford Assay kit was purchased from Thermo Scientific. XT sample buffer, XT reducing agent, Precision Plus Protein ladder, Gels One, and TGX homogenous Prestained Molecular Weight Marker, and Precision Plus Molecular Weight Standards were purchased from Bio-Rad. Primary antibodies used for Western blotting (WB) include the following: claudin-5 [Invitrogen (Thermo Fisher), catalog #OC-3F10, 1:1000], and occludin [Invitrogen (Thermo Fisher), catalog #4C3C2, 1:500], and α-tubulin ([Cell Signaling, catalog #DM1A, 1:5000). Secondary antibodies for WB were purchased from Cell Signaling Technology and used at a 1:20,000 dilution. All other chemicals were purchased from Sigma-Aldrich.

Dural cannulation

Anesthesia was induced with intraperitoneal 80:12 mg/kg ketamine:xylazine. Rats were placed in a stereotactic frame (Stoelting Co.), and a 1.5- to 2-cm incision was made to expose the skull. A 0.66- to 1-mm hole (Pinprick/KCl: -6 mm A/P, -3 mm M/L from bregma) was made with a hand drill (DH-0 Pin Vise; Plastics One) to carefully expose, but not damage, the dura. A guide cannula (0.5 mm from top of skull, 22 GA, #C313G; Plastics One) was inserted into the hole and sealed into place using dental cement. Animals were housed individually and allowed 2–3 d to recover. Only those rats with stable electrocorticographic (ECoG) recordings were included in experimental groups. Signals leading to separate DC and AC amplifiers (Grass Model 15 amplifier system, 15A12 DC and 15A54 AC amplifiers, Astro-Med Inc.) through insulated cables and digital recording devices were collected with EEG recording analysis software Gamma v.4.9 (Astro-Med, Inc.). The recording data were reviewed with Gamma Reviewer (Astro-Med, Inc.) and analyzed for SD events offline. SD was defined by significant reductions in both the power and amplitude of the EEG tracings and was only considered as an event when (1) the AC current was reduced by half; (2) the DC current exhibited a downward shift by a minimum of 1mV; and (3) the duration was a minimum of 30 s.

Cortical injections

Cortical injections were performed by employing a Hamilton injector (30 GA, #80308 701 SN, Hamilton Company) customized to project 1.0 mm into the brain. The injector was inserted through the guide cannula to deliver a focal injection of 0.5 μl of 1 M KCl or artificial CSF (aCSF) into the cerebral cortex. aCSF was comprised of 145 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.2 mM CaCl2, and 2 mM Na2HPO4 (pH 7.4), and the solution was passed through a 0.2-μm syringe filter before injection.

Precortical injection treatments

Topiramate (40 mg/kg in suspension) or vehicle (saline) was injected intraperitoneally (IP) 30 min before cortical injection of either KCl or aCSF. Permeability of the BBB was assessed 1.5 h postcortical injection.

Implantation of recording electrodes

Silver chloride (AgCl) electrodes were prepared by flaming 0.25 mm Ag wire (A-M Systems, Inc.) into spherical tips (1 mm in diameter) and coating the tips with Cl-. Rats were anaesthetized with ketamine/xylazine (as above) then fixed to a stereotaxic frame (Stoelting). Three burr holes were drilled through the skull using a manual drill to allow placement of the AgCl recording electrodes. The frontal and parietal lead electrodes were placed from bregma: 2 mm lateral and 1.5 mm anterior, 2 mm lateral and -2.5 mm posterior to bregma, respectively; the reference electrode was placed -7.5 mm A/P, 2 mm M/L. Two screws (#MPX-080-3F-1M, Small Parts Inc.) were fastened into the skull without going through it. The four electrodes were soldered into a multi-pin connector (Continental Connector), and the apparatus was fixed into place using dental cement. Animals were housed individually and allowed 2–3 d to recover to ensure electrode integrity for recordings.

Electrophysiological recordings

Forty-eight hours after dural electrode implantation, rats were placed in a recording chamber (40 cm long × 49 cm wide × 37 cm high) and the multi-pin connector attached to an electro-cannular swivel (#CAY-675-6 commutator, Airlyfe) mounted in the ceiling of the chamber. The swivel allowed rats to move freely about the chamber during the recording period. Animals were allowed to habituate to the chamber for 2 h to permit electrical recordings to stabilize. Only those rats with stable electrophysiological recordings were included in experimental groups. Signals leading to separate DC and AC amplifiers (Grass Model 15 amplifier system, 15A12 DC and 15A54 AC amplifiers, Astro-Med Inc.) through insulated cables and were collected with EEG recording analysis software Gamma v.4.9 (Astro-Med, Inc.). The recording data were reviewed with Gamma Reviewer (Astro-Med, Inc.) and analyzed for SD events offline. SD was defined by significant reductions in both the power and amplitude of the EEG tracings and was only considered as an event when (1) the AC current was reduced by half; (2) the DC current exhibited a downward shift by a minimum of 1mV; and (3) the duration was a minimum of 30 s.
Behavioral assessment

Periorbital allodynia was evaluated before and at 0.5, 1, 1.5, 3, 6, 24–72 h after cortical injection. Rats were grouped based on their postsurgical baseline to ensure equivalent preinjection thresholds, any rats exhibiting excessive postsurgical allodynia (threshold <4 g) were removed from the study. Rats were acclimated to the testing box 90 min before evaluation of periorbital mechanical allodynia with calibrated von Frey filaments (Stoelting). Calibrated von Frey filaments were applied perpendicularly to the midline of the forehead at the level of the eyes until the filament was slightly bent while held for 5 s. A positive response was indicated by a sharp withdrawal of the head or vocalizing. The withdrawal threshold was determined using a modified version of the Dixon up-down method, where the response pattern was used to obtain the threshold as reported by Chaplan et al. (1994). Rearing events were assessed for 5-min intervals before and at 0.5, 1, 1.5, 3, 6, 24–72 h after cortical injection. Vertical rears were counted each time a rat stood on both hind paws without grooming.

In situ brain perfusion

Briefly, rats were anesthetized with ketamine/xylazine (as described above) and heparinized (10,000 U/kg, i.p.). Body temperature was maintained at 37°C using a heating pad. The common carotid arteries were bi-laterally cannulated and connected to a perfusion circuit. The perfusate was an erythrocyte-free modified mammalian Ringer’s solution: 117 mM NaCl, 4.7 mM KCl, 0.8 mM MgSO₄, 1.2 mM KH₂PO₄, 2.5 mM CaCl₂, 10 mM D-glucose, 3.9% (w/v) dextran (MW 60,000), and 1.0 g/l bovine serum albumin (Type IV), pH 7.4, warmed to 37°C and oxygenated with 95% O₂/5% CO₂, Evan’s blue dye (55 mg/l) was added to the perfusate to serve as a visual marker of BBB integrity. Perfusion pressure and flow rate were maintained at 95–105 mmHg and 3.1 ml/min, respectively. The meninges and choroid plexus were removed, cerebral hemispheres were sectioned and the brain was divided into two hemispheres and placed into preweighed vials. TS2 tissue solubilizer (1 ml) was added, along with 1.5 ml Optiphase SuperMix liquid scintillation cocktail (PerkinElmer). Perfusate media was also sampled and placed in triplicate 100–µl aliquots in scintillation vials and processed in the same manner as the tissue samples. All samples were then measured for disintegrations per minute (dpm; 1450 LSC and Luminescence Counter; PerkinElmer). The ratio of the concentration of ¹⁴C-sucrose or ³H-sumatriptan in tissue (Cbrain; in dpm/g) was compared with perfusate (Cperfusate; in dpm/ml) and expressed as a percentage ratio (RBR) Rbrain = (Cbrain/Cperfusate) × 100%.

Cortical tissue collection

Rats were anesthetized with ketamine/xylazine mix as described above, decapitated, and the cortices placed in ice-cold collection buffer (136.9 mM NaCl, 2.7 mM KCl, 1 mM CaCl₂, 1.5 mM KH₂PO₄, 8.1 mM Na₂HPO₄, 0.5 mM MgCl₂, 5 mM glucose, and 1 mM sodium pyruvate; pH 7.4) supplemented with Roche EDTA-free Complete Protease Inhibitor cocktail, Sigma protease inhibitor cocktail and 2 mM phenylmethylsulfonyl fluoride. All subsequent steps were performed on ice or at 4°C. Choroid plexus and meninges were removed, three rat brains/treatment were pooled and homogenized in 20-ml collection buffer using a Potter-Elvehjem homogenizer followed by eight strokes in a glass dounce homogenizer by hand. Samples were stored at −80°C until use.

WB

Tissue samples were prepared with inhibitors as described above. Samples were incubated for 10 min at 70°C and centrifuged for 5 min at 13,000 × g at 21°C to separate any solid particles before gel electrophoresis; 10 µg of total proteins from the tissue supernatant were loaded on TGX precast gels and separated by SDS-PAGE and then transferred to polyvinylidene difluoride membranes (Imobilon, Millipore) and blocked at room temperature for 1 h. Primary antibodies and dilutions are given above. All antibodies were diluted in 5% BSA in tris-buffered saline with Tween 20 (TBST). Immunoblots were revealed by enhanced chemiluminescence (WBKLS0500, Millipore) and imaged on photographic film. To visualize multiple bands on the same blot, blots were stripped with Restore Western Blot Stripping buffer (Pierce, Thermo Fisher). Films were scanned, digitized, and quantified using Un-Scan-It gel version 6.1 scanning software (Silk Scientific Inc.). Protein expression of TJ proteins were corrected for expression of the loading control α-tubulin to normalize for protein expression.

Statistical analysis

GraphPad Prism 7.0 software (GraphPad Software) was used for statistical analysis. Unless otherwise stated, the data were expressed as mean ± SEM. Periorbital allodynia measurements and in situ perfusion time course measurements were assessed using a repeated measure two-way ANOVA to analyze differences between treatment groups over time with a Bonferroni test applied post hoc. In rearing experiments, data were expressed as Area Under the Curve (AUC) ± SEM for rears performed for the duration of the time course. Differences between groups were assessed using an unpaired t test with Welch’s correction. Molecular studies were compared by one-way ANOVA. Single timepoint in situ perfusion results were compared by one-way ANOVA and an unpaired t test with Welch’s correction to determine statistical significance. When p values were ≤0.05, they were accepted as statistically significant.
**Results**

**Cortical injection of KCl, but not aCSF, produces nociceptive behaviors**

CSD has been implicated in headache production in both primary and secondary headache disorders. Studies examining the influence of CSD on nociceptive behaviors and BBB changes have used male rats to assess these parameters (Gursoy-Ozdemir et al., 2004; Fioravanti et al., 2011; Olah et al., 2013). It is known, however, that migraine and many of the underlying disorders leading to secondary headache production afflict women more than men (Hu et al., 1999; Haast et al., 2012). Based on these factors we chose to conduct our studies in intact female rats. As a first step to establish this model in female rats, we measured postsurgical facial allodynia following surgical cannula implantation. Postsurgical facial withdrawal thresholds were 5.74 ± 0.47 g compared to facial withdrawal thresholds of 8 g (maximum measured) presurgery. This difference remained unresolved up to 12 d after surgery (data not shown).

To assess the ability of CSD to induce headache-like nociceptive behaviors, rats received a cortical injection of 1 M KCl to disrupt the extracellular ion equilibrium and the development of CSD was monitored (Fioravanti et al., 2011). All rats injected with cortical KCl experienced up to 2 CSD events within the first 2 h of recording postcortical injection. Cortical aCSF injection, on the other hand, did not produce any observed CSD events (Table 1). Rats receiving a cortical KCl (N = 21) injection exhibited significantly reduced periorbital withdrawal thresholds within 0.5 h, which peaked between 1 and 3 h. Facial withdrawal thresholds recovered significantly within 6 h, but remained significantly lower than preinjection baselines for the remainder of the 72-h time course (KCl withdrawal thresholds at 0.5 h 3.04 ± 0.49, p = 0.0003, 1 h 1.23 ± 0.27, p < 0.0001, 1.5 h 0.96 ± 0.22, p < 0.0001, 3 h 1.21 ± 0.41, p < 0.0001, 6 h 2.70 ± 0.41, p = 0.0014, 24 h 2.44 ± 0.39, p = 0.0003, 48 h 2.55 ± 0.48, p = 0.0062, and 72 h 2.27 ± 0.21, p = 0.0045). A separate group of animals receiving a 0.5-μl cortical injection of aCSF (N = 16) did not exhibit significantly decreased facial withdrawal thresholds from baseline at any of the examined time points (Fig. 1) suggesting that headache nociception was not induced. Non-evoked, or pain-suppressed behavior, was also assessed in response to CSD. Previous studies have shown that rearing behaviors are suppressed in response to facial allodynia (Sandweiss et al., 2017; Zhang et al., 2017). The ability of cortical KCl to depress rearing behavior was assessed throughout the 72-h behavioral time course. Throughout the behavioral time course rats given a cortical KCl injection experienced at least one CSD event within the recording period. Rats injected cortically with aCSF did not experience CSD. CSD was marked by a significant reduction in both the power and amplitude of the EEG tracings and was only considered as an event when (1) the AC current was reduced by half; (2) the DC current exhibited a downward shift by a minimum of 1 mV; and (3) the duration was a minimum of 30 s.

**Table 1. Summary of CSD parameters from rats given a cortical injection of either KCl (n = 3) or aCSF (n = 3)**

| Group          | Number of CSD events | EEG percent decrease | Frontal CSD amplitude decrease (mV) | Parietal CSD amplitude decrease (mV) | Duration (s) |
|----------------|----------------------|----------------------|-------------------------------------|--------------------------------------|--------------|
| KCl (1 M)      | 9                    | 64.39 ± 3.16         | 2.56 ± 0.53                         | 2.11 ± 0.47                          | 59.79 ± 5.84 |
| aCSF           | 0                    | N/A                  | N/A                                 | N/A                                  | N/A          |

Figure 1. Cortical injection of 1 M KCl induces periorbital allodynia. A, Prior to surgery rats do not exhibit significant periorbital allodynia (BL). Cortical injection of KCl (1 M, 0.5 μl), but not aCSF (0.5 μl) significantly decreased facial withdrawal thresholds beginning 30 minutes post injection which improved by 6 hours but did not return to pre-injection baseline thresholds during the 72 hour timecourse. * Denotes significant (p < 0.05) differences from post-surgery baseline (pBL). # denotes significant (p < 0.05) differences from aCSF injected group (KCl N = 21, aCSF N = 16).
course, total rearing events were significantly decreased compared to rats injected with aCSF (AUC aCSF 850.5 ± 83.04, N = 10, AUC KCl 302.5 ± 54.45, N = 12, p = 0.0002). These data support the validity of cortical KCl injection in awake, freely moving female rats as a model of CSD-induced episodic headache.

**BBB permeability is increased following cortical KCl injection at time points corresponding to facial allodynia incidence**

The ability of CSD to induce changes in BBB integrity has been demonstrated in a handful of studies in anesthetized animals (Gursoy-Ozdemir et al., 2004; Olah et al., 2013). No studies to date, however, have assessed BBB integrity or permeability in relation to behavioral changes following cortical KCl injection in awake, freely moving rats. Following determination of facial withdrawal thresholds, cortical BBB permeability was assessed using the in situ brain perfusion technique. 14C-sucrose (MW = 342.30 g/mol) was used to evaluate paracellular permeability (leak) at the BBB due to its relative inability to cross the BBB under non-stressed/normal conditions and due to the lack of any known active transport to the brain. Compared to naive rats (RBR 1.68 ± 0.35, N = 8), cortical KCl injection increased BBB permeability of 14C-sucrose in the cortex within 0.5 h (RBR 4.24 ± 0.17 N = 7, p = 0.0217; Fig. 2A). Permeability returned to naive levels within 6 h post-KCl injection (RBR 3.12 ± 0.13, N = 10, p = 0.0002).

*Figure 2. Cortical KCl injection increased BBB permeability to 14C-sucrose in the cortex but not brainstem as assessed with In situ brain perfusion. A, Cortical injection of KCl (0.5 µl, 1M) induced an increase in cortical BBB permeability to 14C-sucrose at 30 minutes post injection. Permeability returned to naive levels (indicated by dashed line) within 6 hours. B, Injection of KCl (0.5 µl, 1M) into the cortex did not produce significant changes in brainstem permeability to 14C-sucrose. Naive values for 14C-sucrose are denoted by the dashed line. The amount of radioactivity in the cortex and brainstem versus the perfusate was expressed as relative brain uptake or RBR%. * Denotes significant (p < 0.05) differences compared to naive uptake (N = 8–10/group/time-point).
Cortical KCl injection does not alter total expression of TJ proteins occludin or claudin-5

Many studies have shown decreases in TJ protein expression in conjunction with changes in BBB permeability. To determine whether cortical KCl-induced BBB leak corresponded to changes in TJ protein expression, we assessed expression of TJ proteins occludin and claudin-5 following cortical KCl treatment. In samples from whole cortex, expression of claudin-5 was statistically unchanged compared to naïve rats following either cortical KCl or aCSF injection (N = 3 pools of three rats; Fig. 3A). Samples from whole cortex also revealed no change in occludin expression in response to either cortical KCl or aCSF (N = 3 pools of three rats; Fig. 3B). This data suggests that other changes in BBB structure (i.e., TJ protein localization) are likely involved in eliciting the permeability changes seen in response to cortical KCl-induced CSD.

Cortical KCl injection increases BBB permeability to radiolabeled sumatriptan

Sumatriptan is a drug used as an abortive agent for the treatment of migraine. Additionally, sumatriptan has been reported to improve secondary headaches resulting from several conditions including meningitis and subarachnoid hemorrhage (Ferrari et al., 2002; Ahn and Basbaum, 2005; Girdley and Rifkin, 2012). Studies have shown minimal cross-mating of sumatriptan through the BBB, suggesting it works primarily in the periphery (Ahn and Basbaum, 2005); however, some experiments have demonstrated the ability of triptans such as sumatriptan to act as direct inhibitors of second order neurons in the TNC in the brainstem (Cumberbatch et al., 1997; Goadsby et al., 2001). Permeability to \(^{3}H\)-sumatriptan (mw/295.402 g/mol) was determined 1.5 h after cortical KCl injection. The 1.5-h time point was chosen for this and subsequent experiments based on behavioral data showing peak facial allodynia 1.5 h postinjection as well as significant BBB leak (Table 2). Uptake of \(^{3}H\)-sumatriptan was initially assessed in naïve rats and showed minimal uptake in both the cortex and brainstem; consistent with previous studies (Table 2). Consistent with results seen using \(^{14}C\)-sucrose, uptake of \(^{3}H\)-sumatriptan was significantly increased in the cortex 1.5 h post-KCl injection (naïve RBR 2.50 ± 0.29 N = 11, KCl RBR 3.756 ± 0.41 N = 8, p = 0.0182\(^{bc}\); Fig. 4A). In contrast to the results using \(^{14}C\)-sucrose, uptake of \(^{3}H\)-sumatriptan was also robustly increased in the brainstem 1.5 h postinjection (naïve RBR 2.12 ± 0.35 N = 11, KCl RBR 4.03 ± 0.25 N = 8, p = 0.0004\(^{bc}\); Fig. 4B). As with studies using \(^{14}C\)-sucrose, rats injected with cortical aCSF had no significant change in BBB permeability compared to naïve rats (Fig. 4A, B). These data suggest the ability of sumatriptan, to reach headache relevant CNS via active transport in brainstem areas such as the TNC, where it may exert additional therapeutic actions.

Acute topiramate does not prevent increased BBB permeability in response to cortical KCl injection

Topiramate is an anti-epileptic drug which has also been employed for the prevention of primary headache disorders such as migraine (Akerman and Goadsby, 2005). Studies have shown that topiramate can block CSD production in response to cortical KCl application (Akerman and Goadsby, 2005; Unekawa et al., 2012). To assess whether a single injection of topiramate, as a CSD...
preventative, blocked observed cortical BBB leakiness in response to KCl, topiramate or vehicle (saline) was given 30 min before cortical KCl injection. Increased BBB permeability to $^{14}$C-sucrose in response to cortical KCl injection was not prevented by pretreatment with topiramate (topiramate/H11001 KCl RBR 1.091/H11006 0.4856 N/H11005 23, vehicle/H11001 KCl RBR 1.314/H11006 0.5571 N/H11005 22b,c; Fig. 5A). In rats given cortical aCSF injections, topiramate produced no significant changes in $^{14}$C-sucrose uptake compared to those treated with vehicle, suggesting that topiramate alone does not produce changes in BBB permeability (topiramate/aCSF RBR 0.9405/H11006 0.3069 N/H11005 17, vehicle/aCSF RBR 0.8902/H11006 0.3411 N/H11005 21b,c; Fig. 5A). Additionally, in agreement with permeability data shown in Figure 2, no significant changes were seen in $^{14}$C-sucrose uptake within the brainstem in any treatment group (Fig. 5B).

Importantly, pretreatment with a single dose of topiramate did not significantly prevent KCl-induced periorbital allodynia (data not shown). In prior experiments, KCl-induced periorbital allodynia and BBB leak occurred on a similar time course. These data suggest that pretreatment with a single dose of topiramate is not sufficient to prevent cortical KCl-induced BBB leakiness and that the mechanism of barrier leak may be multifaceted, related to both nociceptive transmission as well as other neurovascular mechanisms (Table 3).

### Discussion

In conditions such as TBI and ischemic stroke, the integrity of the BBB is altered following injury (Prakash and Carmichael, 2015), although this loss of integrity is most often associated with trauma within the CNS rather than with CSD or headache. Additionally, in studies examining primary headache disorders, where no obvious CNS trauma exists, CSD and increased BBB permeability have been shown to occur in some instances (i.e., migraine with aura; Leira et al., 2007; Charles and Baca, 2013; Fried et al., 2017). The data presented here represent the first study examining, concurrently, the temporal occurrence of CSD, nociceptive behaviors, and BBB leak in a CSD-induced model of episodic headache. Our data suggest that KCl-induced CSD in awake, freely moving female rats increases cortical, but not brainstem, BBB paracellular permeability to $^{14}$C-sucrose. This permeability change occurs in parallel to CSD events and periorbital allodynia. Importantly, this model was designed without

### Table 2. Summary of values from significant effects of cortical KCl at the 1.5-h time point compared to naive values

| Treatment group | Parameter                  | Value                        |
|-----------------|----------------------------|------------------------------|
| Naive           | Cortex, $[^{14}\text{C}]$-sucrose RBR | 1.68 ± 0.32% weight          |
| Naive           | Cortex, $[^{3}\text{H}]$ sumatriptan RBR | 2.50 ± 0.29% weight          |
| Naive           | Brainstem, $[^{3}\text{H}]$ sumatriptan RBR | 2.13 ± 0.35% weight          |
| Postsurgical baseline | Facial withdrawal threshold | 5.74 ± 0.47 g               |
| Cortical KCl (1 M, 0.5 µl) | Cortex, $[^{14}\text{C}]$ sucrose RBR | 3.12 ± 0.13% weight          |
| Cortical KCl (1 M, 0.5 µl) | Cortex, $[^{3}\text{H}]$ sumatriptan RBR | 3.76 ± 0.41% weight          |
| Cortical KCl (1 M, 0.5 µl) | Brainstem, $[^{3}\text{H}]$ sumatriptan RBR | 4.03 ± 0.25% weight          |
| Cortical KCl (1 M, 0.5 µl) | Facial withdrawal threshold | 0.96 ± 0.22 g               |

For reference, statistically significant BBB leak and facial allodynia were also observed in Figs. 1, 2.

![Figure 4](https://example.com/f4.png)

**Figure 4.** Cortical KCl injection increased both cortical and brainstem BBB permeability to $^{3}$H-sumatriptan as assessed by In situ brain perfusion. **A**, Leakiness of the BBB to $^{3}$H-sumatriptan was observed in response to cortical KCl injection compared to naive values. No significant difference was observed between naive rats and those given a cortical aCSF injection. **B**, Brainstem permeability to $^{3}$H-sumatriptan was also increased in response to cortical KCl injection 1.5 hours after injection. The amount of radioactivity in the cortex and brainstem versus the perfusate was expressed as relative brain uptake or RBR%. * Denotes statistically significant (p < 0.05) differences compared to naive uptake. (Naive N = 11, aCSF N = 7, KCl N = 8).
induction of other CNS injuries such as ischemia or trauma to isolate the temporal integrity of the BBB during CSD and periorbital allodynia. Furthermore, we found increased uptake of $^3$H-sumatriptan in both the cortex and, contrary to $^{14}$C-sucrose studies, the brainstem in response to KCl-induced CSD (findings summarized in Fig. 6). This observation suggests the possibility for changes in active transport in the brainstem of triptans in response to CSD events. Therefore, the efficacy of these anti-migraine drugs may be partially dependent on increases in active transport mechanisms to reach central sites of action during CSD events. Together, our results support the dynamic nature of the BBB, during CSD events the paracellular integrity of the BBB is compromised and in turn may contribute to headache pathology and anti-migraine drug access to the CNS.

**Behavioral analysis of CSD-induced nociceptive behaviors**

Studies examining the influence of CSD on nociceptive behaviors and BBB changes have used male rats to assess these parameters (Gursoy-Ozdemir et al., 2004; Fioravanti et al., 2011; Olah et al., 2013; Zhao and Levy, 2016). It is known, however, that migraine and many of the underlying disorders leading to secondary headache production afflict women more than men (Hu et al., 1999; Haast et al., 2012). A higher percentage of women migraineurs are also reported to seek medical care, and use triptans, more often than men (Brusa et al., 2015). Additionally, it has been suggested that women are more susceptible to secondary headache production in both traumatic brain injury and ischemic stroke compared to males (Tentschert et al., 2005; Lucas et al., 2012).

Head pain is the most prominent feature of both primary and secondary headaches, however, use of anesthesia in previous studies has precluded assessment of periorbital allodynia when studying changes in BBB integrity during CSD. Using surgically implanted guide cannulae, we circumvented the need for anesthesia when applying KCl to the cortex (Fioravanti et al., 2011). Following surgery, we observed significant postsurgical facial allodynia in our female rats, which was not paralleled in studies done in male rats (Fioravanti et al., 2011). Clinically, females have been observed to exhibit longer-lasting postsurgical pain with a higher intensity than males (Morin et al., 2000; Storesund et al., 2016). Following cortical KCl injection, the production of CSD events was confirmed with electrophysiological recordings in awake, freely moving rats. Furthermore, significant periorbital allodynia developed within 0.5 h post-KCl injection and peaked after 1.5 h. Although withdrawal thresholds improved close to baseline levels within 6 h, thresholds remained statistically lower up to 72 h post-KCl injection. Notably, the time of BBB opening corresponded to the peak duration of periorbital allodynia as assessed behaviorally. Non-evoked measures of nociceptive behavior such as rearing have also been used to assess responses in preclinical models of headache (Sandweiss et al., 2017; Zhang et al., 2017). Decreases in these non-evoked exploratory behaviors have been suggested to indicate a decrease in quality of life in these animals. In these studies rats injected with cortical KCl had decreased rearing activity, indicating general discomfort and stress in these animals. These data provide further evidence for CSD as a contributing event in the development of headache pain in primary and secondary headaches.

**Table 3. Summary of Statistical Analyses used. Differences were considered significant at $p < 0.05$**

| Data structure | Type of test          | Power          | Notes                        |
|----------------|----------------------|----------------|------------------------------|
| a. Normal distribution | Two-way ANOVA       | $p < 0.05$     |                              |
| b. Normal distribution | Unpaired t test with Welch's correction | $p < 0.05$     |                              |
| c. Normal distribution | One-way ANOVA       | $p < 0.05$     |                              |

Figure 5. Pre-treatment with topiramate 30 minutes prior to CSD induction with cortical KCl did not prevent KCl induced BBB leakiness to $^{14}$C-sucrose as assessed by In situ brain perfusion. A, Cortical KCl injection increased $^{14}$C-sucrose uptake in the cortex. This increase in leak was not changed by pre-treatment with the anti-epileptic and headache prophylactic drug topiramate. B, No significant difference were observed in brainstem permeability to $^{14}$C-sucrose in response to either KCl or topiramate. Topiramate did not alter BBB permeability in either the cortex or brainstem in control, vehicle/aCSF treated rats. The amount of radioactivity in the cortex and brainstem versus the perfusate was expressed as relative brain uptake or RBR%. NS denotes no significant difference between groups. * Denotes significant ($p = 0.0279$) differences compared to vehicle/aCSF treated rats (vehicle/aCSF $N = 21$, topiramate/aCSF $N = 17$, vehicle/KCl $N = 22$, topiramate KCl $N = 23$).

July/August 2018, 5(4) e0116-18.2018
secondary headache disorders. Importantly, no significant periorbital allodynia was seen in rats given a cortical aCSF injection, indicating that these changes were due to KCl application and not the injection itself. Therefore, our current studies in female rats recapitulated clinical observations in headache populations to validate our model.

**BBB changes in response to CSD**

One third of migraineurs experience focal neurologic symptoms known as aura (Silberstein, 2001). CSD originating in the occipital lobe is thought to contribute to the initiation of the aura phase of migraine with aura (Leo, 1944; Leao, 1947; Somjen, 2001). Aura is highly variable between patients and may have sensory, motor, verbal, auditory, or olfactory components, suggesting generalized cortical dysfunction. Onset of aura can occur during the premonitory phase and persist throughout the headache phase (Goadsby et al., 2017). Interestingly, numerous clinical studies have shown that sumatriptan, the most common drug used for the treatment of migraine, is most effective when given in the premonitory/aura phase or soon after the start of the headache phase (Bigal and Lipton, 2008; Aurora et al., 2009; Bigal et al., 2009; Gilmore and Michael, 2011; Thorlund et al., 2014; Martelletti, 2015). These observations suggest the possibility for changes in drug delivery dynamics to occur over the course of migraine progression. Studies assessing the CSD contribution to altered BBB integrity have shown increased paracellular leak following CSD induction (Gürsoy-Ozdemir et al., 2004; Olah et al., 2013), although previous changes in BBB integrity in the context of CSD were performed in highly invasive models in anesthetized rats. In our model, we observed increased paracellular leak with a short onset latency (0.5 h) and fast resolution.
(within 6 h). The time points at which we observed BBB leakiness differ from a previous study (Gursoy-Ozdemir et al., 2004) where increased permeability to Evan’s Blue was seen up to 24 h following CSD induced with cortical pinprick. Several components in our model may account for these differences. One possibility is that we reduced the contribution of surgical trauma to BBB measurements in our model via dural cannula placement. In the studies done by Gursoy-Ozdemir et al. (2004), an exaggerated BBB response to CSD may have occurred due to ongoing surgical trauma resulting from use of cranial windows and dural retraction; these stresses may diminish barrier function alone (Spong et al., 2014). Additionally, our use of female rather than male rats may account for our observed differences; for instance, it has been shown that female sex hormones are protective against BBB disruption and repress MMP production (Cipolla et al., 2009; Khakarsi et al., 2011; Na et al., 2015; Maggioli et al., 2016). On the other hand, we observed significant postsurgical facial allodynia and a more exaggerated nociceptive response to KCl in our female rats compared to those reported in male rats (Fioravanti et al., 2011). Therefore, it is possible that, due to hormonal effects, our female rats experienced both a more intense nociceptive response, leading to both a rapid onset and resolution of BBB disruption following KCI-induced CSD. These data suggest the possibility for differing mechanisms of increased BBB permeability in response to CSD in male versus female subject. Despite these differences in conditions, our data support increased paracellular permeability of the BBB following KCI-induced CSD events, which may influence drug delivery to the CNS.

The brainstem contains several processing centers important for the transmission and modulation of pain, including headache (Ossipov et al., 2010). For example, the second order neurons responsible for receiving nociceptive information from peripheral trigeminal nociceptors are in the TNC in the brainstem (Hoskin et al., 2001; Liu et al., 2009). Therefore, changes in permeability at the brainstem, an important target area for headache therapeutics, may be particularly relevant for drug delivery during headache. Although studies done in an inflammation induced model of headache showed changes in BBB permeability in the brainstem, namely the TNC (Fried et al., 2017), our studies revealed that cortical KCl injection did not increase paracellular permeability in the brainstem as measured by $^{14}$C-sucrose. This suggests the possibility of model-specific alterations in BBB permeability. One possible explanation for this is that KCI-induced CSD does not spread to the brainstem. In fact, it has been demonstrated that the brainstem is resistant to spreading depression originating from the cortex (Andrew et al., 2017).

Some clinical studies have also examined BBB changes in response to episodic headache, particularly migraine. These studies, however, have produced conflicting results. Increased MMP-9 activity was observed in one study during migraine headache attacks, indicating a breakdown of the BBB (Leira et al., 2007). Conversely, a PET imaging study done during glyceryl trinitrate (GTN)-induced migraine showed no increase in BBB permeability to $^{11}$C-dihydroergotamine (Schankin et al., 2016). This study was performed in an artificial induction model, however, which may not produce all of the complex features of migraine. Additionally, a recent MRI study demonstrated no change in BBB permeability in spontaneous attacks of migraine with aura (Hougaard et al., 2017). Importantly, this study represented the first highly sensitive imaging assessment of spontaneously occurring migraine with aura. Though the data from this clinical study suggest an opposing conclusion from those presented here, some differences in experimental parameters may explain these discrepancies. First, the timing of observation was significantly different from our studies. The average time from onset of aura to imaging in the MRI study was 7.6 h (Hougaard et al., 2017). In our study, however, we observed an immediate increase in BBB permeability which resolved very quickly (within 6 h). It is therefore possible that this clinical MRI study missed the time period corresponding to increased barrier permeability. Additionally, this MRI study consisted of 19 patients, which were genetically diverse and mixed-sex (Hougaard et al., 2017). Since migraine disorders are complex and, likely, arise from a multitude of different origins, it is possible that increased BBB permeability is not a feature which occurs in all migraine with aura variants. Still, based on other clinical studies as well as our own data, it is likely that increased BBB permeability occurs in at least some variants of migraine as well as in other primary or secondary headache disorders.

Changes in CNS uptake of migraine therapeutics

Migraine-specific medications are used to combat migraine, with emphasis on moderate to severe migraine (Bigal et al., 2009; Martelletti, 2015; Starling and Dodick, 2015). Triptans are first-line therapies for episodic migraine associated with high therapeutic gains and favorable side-effect profiles (Humphrey et al., 1990; Ferrari, 1998; Gilmore and Michael, 2011; Smitherman et al., 2013; Thorlund et al., 2014). These serotonin (5HT) derivatives constitute 80% of migraine prescriptions (Smitherman et al., 2013); sumatriptan represents ~50% of the market (Smitherman et al., 2013). Only ~30% of patients have reduced head pain intensity and duration with triptan compounds (Malone et al., 2015; Smitherman et al., 2013; Burgos-Vega et al., 2015). Importantly, migraineurs report that triptans need to be on-board during prodrome for effect and that triptans are less effective when taken at the headache phase (Bigal and Lipton, 2008; Bigal et al., 2009; Gilmore and Michael, 2011; Thorlund et al., 2014; Martelletti 2015) suggesting an unknown pharmacokinetic/dynamic mechanism of action that may relate to BBB/NVU integrity. Using $^{3}$H-sumatriptan, a drug not typically thought to cross the BBB, we again observed increased BBB leakiness in the cortex following cortical KCl injection. Surprisingly, and in contrast with our data with $^{14}$C sucrose, we saw a robust increase in brainstem uptake of $^{3}$H-sumatriptan 1.5 h post-KCl injection. This disparity between $^{14}$C-sucrose and $^{3}$H-sumatriptan in the brainstem may be explained by changes in active transport. While sucrose has no known endogenous transporter, sumatriptan...
has at least one putative transporter, the influx transporter organic anion-transporting polypeptide (OATP) 1A2 (rat Oatp1a4), although its role in transporting sumatriptan to the CNS has yet to be elucidated (Cheng et al., 2012). Furthermore, increases in the function and expression of Oatp1a4 have been observed at the BBB in response to inflammatory pain as well as hypoxia/reoxygenation stress (Ronaldson et al., 2011; Thompson et al., 2014). It has yet to be determined, however, whether migraine or other headache disorders produce similar changes in brainstem Oatp1a4/OATP1A2. Further investigation is warranted, to determine the exact cause of increased sumatriptan uptake in the brainstem following cortical KCl injection. The observed increase in brainstem uptake of sumatriptan may represent an opportunity for triptans such as sumatriptan, which do not normally cross to the CNS in appreciable levels to exert a therapeutic effect in these relevant brainstem areas. Therefore, with the proper timing of dosing, these drugs may be able to achieve a greater therapeutic efficacy in the indicated migraine population with expanded use to secondary headache disorders.

Topiramate is an anti-epileptic which is also used as a migraine prophylactic. Topiramate functionally modulates voltage gated sodium and calcium channels, GABA receptor potentiation, and blockade of glutamatergic transmission (Akerman and Goadsby, 2005). Important to this study, a single application of topiramate has been shown to block CSD initiation (Akerman and Goadsby, 2005; Unekawa et al., 2012; Green et al., 2014). We observed that topiramate pretreatment was not able to block KCl-induced BBB leakiness. Additionally, periorbital allodynia was unaffected with topiramate pretreatment. Since topiramate therapy for migraine is often prophylactic to reduce migraine attack frequency and magnitude (Martelletti, 2015; Zhangetal., 2010; Silberstein, 2017), and not abortive, it is possible that repeated administration of topiramate is required to have effects on periorbital allodynia in this model. Thus, present findings suggest that regulation of BBB integrity and nociception in response to a single KCl injection arise concurrently from separate, and likely complex, mechanisms.

Concluding remarks
Disorders resulting in primary and secondary headache production arise from distinct etiologies. Although their pathologies are varied, the development of CSD remains a common event among them (Olesen et al., 1990; Hadjikhani et al., 2001; Bolay et al., 2002; Dreier et al., 2006; Hartings et al., 2009; Zhang et al., 2010; Lauritzen et al., 2011; Woitzik et al., 2013; Chen and Ayata, 2016). In already compromised tissue (i.e., in ischemic stroke), CSD has been demonstrated to facilitate neuronal death (Dreier and Reiffurth, 2015; Androulakis et al., 2016). Conversely, CSD occurring in otherwise “normal” tissue, such as in migraine with aura, is seen as relatively benign; although it may contribute to an increased risk for stroke occurrence (Santos et al., 2012). Changes in BBB permeability have been shown in numerous disease states to further contribute to CNS damage (Friedman and Kaufor, 2015). On the other hand, transient disruptions in BBB permeability resulting from conditions such as migraine with aura/CSD may provide an opportunity to facilitate drug delivery to the CNS, potentially improving disease outcomes. In conditions such as TBI and ischemic stroke, the integrity of the BBB is altered following injury (Prakash and Car michael, 2015), although this loss of integrity is most often associated with trauma within the CNS rather than with CSD or headache.

This study represents a novel, parallel observation of both nociceptive behavior and BBB changes in a minimally invasive model of CSD induction in awake, freely moving rats. Overall, the data presented here supports the proposition of increased BBB permeability and compromised integrity of the microvasculature in response to CSD. Furthermore, our studies suggest that these changes influence CNS uptake of the abortive ant-migraine agent, sumatriptan. The ability of drugs to penetrate the BBB remains the most significant obstacle in the development of drugs for disease with a CNS component. Previous reports have shown little to no CNS penetration of sumatriptan (Ahn and Basbaum 2005). The data presented here, however, suggests an enhanced uptake of sumatriptan to the CNS following CSD and headache production that is temporarily dependent, potentially leading to alterations in therapeutic efficacy. Therefore, this study highlights the importance of uncovering pathologic regulation of BBB integrity, to facilitate development effective therapeutic regimens for CNS mediated pathologies. Based on these findings, further investigation is warranted to determine the precise mechanisms driving the BBB changes observed response to KCl-induced CSD.

References
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37:13–25. CrossRef Medline
Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115:1–4. CrossRef Medline
Akerman S, Goadsby PJ (2005) Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuronreport 16:1383–1387. Medline
Andrew RD, Hsieh YT, Brisson CD (2017) Spreading depolarization triggered by elevated potassium is weak or absent in the rodent lower brain. J Cereb Blood Flow Metab 37:1735–1747. CrossRef
Androulakis XM, Kodumuri N, Giambardino LD, Rosamond WD, Gottesman RF, Yim E, Sen S (2016) Ischemic stroke subtypes and migraine with visual aura in the ARIC study. Neurology 87:2527–2532. CrossRef Medline
Asghar MS (2012) Effects of glyceryl trinitrate and calcitonin gene-related peptide on BOLD signal and arterial diameter: methodological studies by fMRI and MRA. Dan Med J 59:B4489.
Aurora SK, Barrodale PM, McDonald SA, Jakubowski M, Burststein R (2009) Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 49:1001–1004. CrossRef Medline
Bigail ME, Lipton RB (2008) Excessive acute migraine medication use and migraine progression. Neurology 71:1821–1828. CrossRef
Bigail ME, Krymchantowski AV, Ho T (2009) Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq Neuropsiquiatr 67:559–569. Medline
Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142. CrossRef
Bolay B, Berman NE, Akcali D (2011) Sex-related differences in animal models of migraine headache. Headache 51:891–904. CrossRef
Brennan KC, Beltrán-Parrazal L, López-Valdés HE, Theriot J, Toga AW, Charles AC (2007) Distinct vascular conduction with cortical spreading depression. J Neurophysiol 97:4143–4151. CrossRef Medline
Brusa P, Allais G, Rolando S, Baratta F, Giacone M, Bussone G, Allais R, Benedetto C (2015) Migraine attacks in the pharmacy: a gender subanalysis on treatment preferences. Neuroul Sci 36 [Suppl 1]:93–95. CrossRef
Burgos-Vega C, Moy J, Dusser G (2015) Meningeal afferent signaling and the pathophysiology of migraine. Prog Mol Biol Transl Sci 131:537–564. CrossRef Medline
Chal NC, Peterlin BL, Calhoun AH (2014) Migraine and estrogen. Curr Opin Neuroul 27:315–324. CrossRef Medline
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yakshe L (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63. Medline
Charles AC, Baca SM (2013) Cortical spreading depression and migraine. Nat Rev Neurol 9:637–644. CrossRef Medline
Chen SP, Ayata C (2016) Spreading depression in primary and secondary headache disorders. Curr Pain Headache Rep 20:44. CrossRef Medline
Cheng Z, Liu H, Yu N, Wang F, An G, Xu Y, Liu Q, Guan CB, Ayton A (2012) Hydrophic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier. Xenobiotica 42:880–890. CrossRef
Cipolla MJ, Godfrey JA, Wiegman MJ (2009) The effect of ovariec- tomy and estrogen on penetrating brain arteries and blood-brain barrier permeability. Microcirculation 16:685–693. CrossRef
Cumberbatch MJ, Hill RG, Hargreaves RJ (1997) Rizatriptan has inflammatory dural stimulation in a rat model of chronic trigeminal specific disruption of the blood-brain barrier following repeated mechanical insults. Ann Neurol 50:804–807. Medline
Curtis BA, Allais G, Rolando S, Baratta F, Giaccone M, Bussone G, Brenner KC, Beltrán-Parrazal L, López-Valdés HE, Theriot J, Toga AW, Charles AC (2007) Distinct vascular conduction with cortical spreading depression. J Neurophysiol 97:4143–4151. CrossRef Medline
Dreier JP, Reiffurth C (2015) The stroke-migraine depolarization continuum. Neuron 86:1063–1068. CrossRef Medline
Dreier JP, Woitzik J, Fabricius M, Chavdarova M, Strong AJ, Lauritzen M, Strong AJ, Fabricius M, Manning A, Bhatia R, Dreier JP, Lauritzen M, Dreier JP, Fabricius M, Strong AJ, Strong AJ, Fabricius M, Manning A, Bhatia R, Dreier JP (2015) Localization of CGRP, CGRP receptor, PACAP and gluta- mate in trigeminal ganglion. Relation to the blood-brain barrier. Brain 129:3224–3237. CrossRef
Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L (2015) Fos expression in the midbrain periaqueductal grey after intracranial hemorrhage, and traumatic brain injury. Can J Physiol Pharmacol 89:31–40. CrossRef
Faria V, Erpelding N, Lebel A, Johnson A, Wolff R, Fair D, Burstein R (2015) Sex differences in modifying blood-brain barrier permeability by NO in pentylenetetrazol-induced epileptic seizures. Life Sci 80:1274–1281. CrossRef
Fisher JP, Reifurch C (2015) The stroke-migraine depolarization continuum. Neuron 86:902–922. CrossRef Medline
Fisher JP, Wotizik J, Fabricius M, Bhatia R, Major S, Drenckhahn C, Brenner KC, Beltrán-Parrazal L, López-Valdés HE, Theriot J, Toga AW, Charles AC (2007) Distinct vascular conduction with cortical spreading depression. J Neurophysiol 97:4143–4151. CrossRef Medline
Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AS, Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F, Murr AS, Cooper RL (2007) The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Res B Dev Reprod Toxicol 80:84–97. CrossRef
Freedman A, Kaufner D (2015) Blood-brain barrier in health and disease. Semin Cell Dev Biol 38:1. CrossRef Medline
Gilmore B, Michael M (2011) Treatment of acute migraine headache. Am Fam Physician 83:271–280. Medline
Girdley FM, Rifkin AR (2012) Headache secondary to mass responsive to sumatriptan: a brief report from primary care. Headache 52:1590–1592. CrossRef Medline
Goadsby PJ, Akerman S, Storer RJ (2001) Evidence for postjunctional serotonin (5-HT1) receptors in the trigemincervical complex. Ann Neurol 50:804–807. Medline
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:553–622. CrossRef Medline
Goldman JM, Murr AS, Cooper RL (2007) The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Res B Dev Reprod Toxicol 80:84–97. CrossRef
Green AL, Pu P, De Felice M, Dodick D, Ossipov MH, Porreca F, Murr AS, Cooper RL (2014) Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 34:594–604. CrossRef
Gurses-Ozdemir Y, Qi J, Matsuoka N, Bolay H, Bempohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447–1455. CrossRef Medline
Haast RA, Gustafson DR, Kiliaan AJ (2012) Sex differences in stroke. J Cereb Blood Flow Metab 32:2100–2107. CrossRef Medline
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Toottel RB, Sorensen AG, Moskowitz MA (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 98:4687–4692. CrossRef Medline
Hartings JA, Strong AJ, Fabricius M, Manning A, Bhatia R, Dreier JP, Mazzeo AT, Tortella FC, Bullock MR, Co-Operative Study of Brain Injury Depolarizations (2009) Spreading depolarizations and late secondary insults after traumatic brain injury. J Neurotrauma 26:1857–1866. CrossRef
Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173–185. CrossRef Medline
He A, Song D, Zhang L, Li C (2017) Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain 18:26. CrossRef
Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. CrossRef
Hoskin KL, Bulmer DC, Lasalandra M, Jonkman A, Goadsby PJ (2001) Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. J Anat 198:29–35. CrossRef
Huang A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP, Larsson HBW, Ashina M (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of mi-graine with aura. Brain 140:1633–1642. CrossRef
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159:813–818. Medline
Humphrey PP, Feniku W, Perren MJ, Beresford IJ, Skingle M, Whal- ley ET (1990) Serotonin and migraine. Ann N Y Acad Sci 600:587–598; discussion 598–600. Medline
Khaksari M, Softani Z, Shahrokhii N, Moshtagh G, Asadikaram G (2011) The role of estrogen and progesterone, administered alone and in combination, in modulating cytokine concentration follow- ing traumatic brain injury. Can J Physiol Pharmacol 89:31–40. CrossRef
Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ (2011) Clinical relevance of cortical spreading depression in neu-rological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab 31:17–35. CrossRef
Leao AA (1947) Further observations on the spreading depression of activity in the cerebral cortex. J Neurophysiol 10:409–414. Cross-Ref Medline

Leira R, Sobrino T, Rodríguez-Yáñez M, Blanco M, Arias S, Castillo J (2007) MMP-9 immunoreactivity in acute migraine. Headache 47:698–702. CrossRef Medline

Leo AA (1944) Spreading depression of activity in the cerebral cortex. J Neurophysiol 7:359–390. CrossRef

Liu Y, Broman J, Zhang M, Edvinsson L (2009) Brainstem and thalamic projections from a craniovascular sensory nerve centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia 29: 935–948. CrossRef

Lucas S, Hoffman JM, Bell KR, Walker W, Dikmen S (2012) Characterization of headache after traumatic brain injury. Cephalalgia 32:600–606. CrossRef Medline

Maggioli E, McArthur S, Mauro C, Kiewsich J, Kusters DH, Reuteringsperger CP, Yaqoob M, Solito E (2016) Estrogen protects the blood-brain barrier from inflammation-induced disruption and increased lymphocyte trafficking. Brain Behav Immun 51:212–222. CrossRef

Malone C, Bhowmick A, Wachholtz A (2015) Migraine: Treatments, comorbidities, and quality of life, in the USA. Journal of Pain Research 2015-5:8357–547. Medline

Martelletti P (2015) The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 11:175–177. CrossRef Medline

Misra UK, Kalita J, Bhoi SK (2013) Allodynia in migraine: clinical observation and role of prophylactic therapy. Clin J Pain 29:577–582. CrossRef Medline

Morin C, Lund JP, Villarroel T, Clokie CM, Feine JS (2000) Differences between the sexes in post-surgical pain. Pain 85:79–85. Medline

Na W, Lee KY, Kim WS, Yune TY, Ju BG (2015) Effects of estradiol ameliorates tight junction disruption via repression of MMP tran-

scription. Mol Endocrinol 29:1347–1361. CrossRef Medline

Olah G, Heredi J, Menyhart A, Czinege Z, Nagy D, Fuzik J, Kocsis K, Knapp L, Krucso E, Gellert L, Kis Z, Farkas T, Fulop F, Pardutz A, Tajti J, Vecsei L, Toldi J (2013) Unexpected effects of peripherally administered kynurenine acetic on cortical spreading depression and related blood-brain barrier permeability. Drug Des Devel Ther 7:981–987.

Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, Karle A (1990) Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 28:791–798. CrossRef Medline

Ossipov MH, Dussor GO, Porreca F (2010) Central modulation of spreading depression. J Neurophysiol 103:359–390. CrossRef Medline

Pitts SR, Niska RW, Yu J, Burt CW (2008) National Hospital Ambulato ry Medical Care Survey: 2006 emergency department summary. Nati Health Stat Report 1–38.

Prakash R, Carmichael ST (2015) Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol 28:556–564. CrossRef

Ronaldson PT, Finch JD, Demarco KM, Quigley CE, Davis TP (2011) Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther 336:827–839. CrossRef

Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552. CrossRef Medline

Sandweiss AJ, Cottier KE, McIntosh MI, Dussor G, Davis TP, Vandera th TW, Largent-Milnes TM (2017) 17-β-estradiol induces spreading depression and pain behavior in alert female rats. On- cotarget 8:114109–114122. CrossRef Medline

Santos E, Sanchez-Porras R, Dohmen C, Hertle D, Unterberg AW, Sakowitz OW (2012) Spreading depolarizations in a case of migraine-related stroke. Cephalalgia 32:433–436.

Schanker CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Spenger T, VanBrocklin HF, Goebaday PJ (2016) Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain 139:1994–2001.

Silberstein SD (2001) Headache and female hormones: what you need to know. Curr Opin Neurol 14:323–333. Medline

Silberstein SD (2017) Topiramate in migraine prevention: a 2016 perspective. Headache 57:165–178. CrossRef Medline

Silberstein SD, Neto W, Schmitt J, Jacobs D (2004) Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61:490–495. CrossRef Medline

Smitherman TA, Burch R, Sheikh H, Loder E (2013) The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 53:427–436.

Somjen GG (2001) Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev 81: 1065–1096. CrossRef Medline

Spong KE, Rochon-Terry G, Money TG, Robertson RM (2014) Disruption of the blood-brain barrier exacerbates spreading depression in the locust CNS. J Insect Physiol 66:1–9.

Starling AJ, Dodick DW (2015) Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care. Mayo Clin Proc 90:408–414. CrossRef Medline

Storesund A, Krukhauyg Y, Olsen MV, Rygh LJ, Nilsen RM, Norekvål TM (2016) Females report higher postoperative pain scores than males after ankle surgery. Scand J Pain 12:85–93.

Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE, Berman NE (2011) Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 51:674–692. CrossRef Medline

Tabatabai RR, Swadron SP (2016) Headache in the emergency department: avoiding misdiagnosis of dangerous secondary causes. Emerg Med Clin North Am 34:695–716.

Terttschert S, Wimmer R, Greisenegger S, Lang W, Lalouchewk W (2006) Headache at stroke onset in 2196 patients with ischemic stroke or transient ischemic attack. Stroke 36:e1–e3. CrossRef Medline

Thompson BJ, Sanchez-Covarrubias L, Slosky LM, Zhang Y, Lar- acuente ML, Ronaldson PT (2014) Hypoxia/reoxygenation stress signals an increase in organic anion transporting polypeptide 1a4 (Oatp1a4) at the blood-brain barrier: relevance to CNS drug delivery. J Cereb Blood Flow Metab 34:699–707.

Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, Goadsby PJ (2014) Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 34:258–267.

Unekawa M, Tomita Y, Toriumi H, Suzuki N (2012) Suppressve effect of chronic peroral topiramate on potassium-induced cortical spreading depression in rats. Cephalalgia 32:518–527.

Wang Q, Shen L, Ma S, Chen M, Lin X, Hong Y, Liang S, Feng Y (2015) Effects of Liguisticum chinanxiang and Gastrodia elata on blood-brain barrier permeability in migraine rats. Pharmazie 70: 421–426.

Woltzik J, Hecht N, Pinczolits A, Sandow N, Major S, Winkler MK, Weber-Carstens S, Dohmen C, Graf R, Strong AJ, Dreier JP, Vajkoczy P; COSBID Study Group (2013) Propagation of cortical spreading depolarization in the human cortex after malignant stroke. Neurology 80:1095–1102.

Zhang M, Liu Y, Zhao M, Tang W, Wang X, Dong Z, Yu S (2017) Depression and anxiety behaviour in a rat model of chronic mi- graine. J Headache Pain 18:27.

Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R (2010) Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 30: 8807–8814.

Zhao J, Levy D (2016) Cortical spreading depression promotes persistent mechanical sensitization of intracranial meningeal affer- ents: implications for the intracranial mechanosensitivity of mi- graine. eNeuro 3.